Search anything
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
Alkem Laboratories has launched semaglutide single-shot pre-filled syringes in India from Rs 350 after DCGI approval, widening Type 2 diabetes and obesity treatment options.
Foreign ownership in NSE-listed companies has dropped to a 17-year low as record FPI outflows clash with rising FDI inflows, per RBI, NSE and NSDL data.
The ED has searched Vedanta offices under FEMA over alleged foreign exchange compliance issues tied to payments to Vedanta Resources, with the company saying it is cooperating fully.
Oyo parent Prism has received Sebi approval for a ₹6,650 crore IPO and is preparing to file its updated offer document by early July after confidential filing in December 2025.
Oyo parent Prism has received Sebi approval for a Rs 6,650 crore IPO, targeting a $7-8 billion valuation while weighing listing timing amid market volatility.
ED searched Vedanta-linked premises in Mumbai and Delhi on June 2 in a FEMA probe into overseas payments such as royalties or brand fees to Vedanta Resources.
Ahead of the June 3-5, 2026 MPC meeting, experts expect no immediate rate cut, while borrowers and FD investors track how repo-rate changes alter EMIs and returns.
Canara Bank’s board has approved raising up to ₹8,500 crore in FY2026-27 through Basel III compliant AT1 and Tier II bonds, subject to market conditions and approvals.
RBI’s annual report and economists flag West Asia-driven oil shocks, supply disruptions and emerging El Niño risks as key drags on India’s FY27 growth and inflation outlook.
RateGain Travel Technologies set its IPO for December 7-9, 2021 with a Rs 405-425 price band, combining a fresh issue and promoter-led offer for sale.
Sebi has cleared PB Fintech’s IPO plan for a Rs 6,017 crore issue, with the Policybazaar and Paisabazaar parent targeting a Diwali window and a $6-7 billion valuation.
CCI has approved UPL’s internal reorganisation that consolidates India and international crop protection businesses into UPL Global, a new listed entity under a composite scheme.
Ironwood Pharmaceuticals said the FDA expanded LINZESS use to children aged 2+ for functional constipation, as the company reported stronger Q1 2026 revenue and reaffirmed 2026 guidance.
Alphabet has guided $175-185 billion in 2026 capex for AI infrastructure, raising investor concerns about returns even as demand for chips, servers and data centres rises.
Prism, Oyo’s parent, has received Sebi approval for a ₹6,650 crore fresh-issue IPO and plans to file an updated offer document for 21-day public comments.
Foreign investors have sold over ₹2 lakh crore of Indian equities in 2026 so far, while domestic institutions bought heavily and softened the impact on prices.
